Latest Quarter
2025-09-30
Grace Therapeutics Inc (GRCE)
Revenue
$0.0
Net Income
-$938K
Operating Margin
N/A
Free Cash Flow
-$14.9M
Debt / Assets
7.5%
Values are in USD and rounded to the nearest whole number unless noted.
Swipe horizontally to view all columns.
| Income Statement (Quarterly) | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Operating Expenses | ||||
| R&D Expenses | 0 | 0 | 0 | 0 |
| SG&A Expenses | 1,961,000 | 2,133,000 | 1,509,000 | 1,853,000 |
| Operating Expenses | 2,529,000 | 3,090,000 | 3,704,000 | 4,831,000 |
| Operating Income | -2,529,000 | -3,090,000 | -3,704,000 | -4,831,000 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Income Before Tax | -938,000 | -3,362,000 | -4,760,000 | -4,284,000 |
| Income Tax Expense | 0 | 0 | -605,000 | -852,000 |
| Net Income | -938,000 | -3,362,000 | -4,155,000 | -3,432,000 |
| Per Share | ||||
| EPS | -0.06 | -0.21 | -0.36 | -0.30 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Statement (Annual) | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Expenses | ||
| R&D Expenses | 0 | 0 |
| SG&A Expenses | 7,161,000 | 6,644,000 |
| Operating Expenses | 16,679,000 | 12,852,000 |
| Operating Income | -16,679,000 | -12,852,000 |
| Interest Expense | 0 | 0 |
| Income Before Tax | -12,767,000 | -14,685,000 |
| Income Tax Expense | -3,199,000 | -1,832,000 |
| Net Income | -9,568,000 | -12,853,000 |
| Per Share | ||
| EPS | -0.79 | -1.73 |
| EPS Diluted | 0.00 | 0.00 |
| Balance Sheet (Quarterly) | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 22,133,000 | 23,005,000 |
| Short Term Investments | 0 | 0 |
| Net Receivables | 126,000 | 722,000 |
| Inventory | 0 | 0 |
| Total Current Assets | 22,712,000 | 24,010,000 |
| Property Plant Equipment | 15,000 | 24,000 |
| Goodwill and Intangibles | 49,266,000 | 49,266,000 |
| Total Assets | 71,993,000 | 73,300,000 |
| Liabilities | ||
| Account Payables | 601,000 | 1,007,000 |
| Short Term Debt | 0 | 0 |
| Total Current Liabilities | 1,930,000 | 1,684,000 |
| Long Term Debt | 0 | 0 |
| Total Liabilities | 5,383,000 | 11,557,000 |
| Shareholders Equity | ||
| Retained Earnings | -220,687,000 | -211,119,000 |
| Total Shareholders Equity | 66,610,000 | 61,743,000 |
| Balance Sheet (Annual) | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 22,133,000 | 23,005,000 |
| Short Term Investments | 0 | 0 |
| Net Receivables | 126,000 | 722,000 |
| Inventory | 0 | 0 |
| Total Current Assets | 22,712,000 | 24,010,000 |
| Property Plant Equipment | 15,000 | 24,000 |
| Goodwill and Intangibles | 49,266,000 | 49,266,000 |
| Total Assets | 71,993,000 | 73,300,000 |
| Liabilities | ||
| Account Payables | 601,000 | 1,007,000 |
| Short Term Debt | 0 | 0 |
| Total Current Liabilities | 1,930,000 | 1,684,000 |
| Long Term Debt | 0 | 0 |
| Total Liabilities | 5,383,000 | 11,557,000 |
| Shareholders Equity | ||
| Retained Earnings | -220,687,000 | -211,119,000 |
| Total Shareholders Equity | 66,610,000 | 61,743,000 |
| Cash Flow Statement (Quarterly) | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Operating Activities | ||
| Net Income | -9,568,000 | -12,853,000 |
| Depreciation & Amortization | 7,000 | 11,000 |
| Stock Based Compensation | 730,000 | 913,000 |
| Change in Working Capital | 342,000 | -1,280,000 |
| Operating Cash Flow | -14,904,000 | -12,333,000 |
| Investing Activities | ||
| Capital Expenditure | 0 | -22,000 |
| Investments | 0 | -22,000 |
| Investing Cash Flow | 0 | 104,000 |
| Financing Activities | ||
| Debt Repayment | 0 | 0 |
| Common Stock Issued/Repurchased | 14,999,000 | 7,338,000 |
| Dividends Paid | 0 | 0 |
| Financing Cash Flow | 14,032,000 | 7,359,000 |
| Summary | ||
| Free Cash Flow | -14,904,000 | -12,355,000 |
| Net Change in Cash | -872,000 | -4,870,000 |
| Cash Flow Statement (Annual) | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Operating Activities | ||
| Net Income | -9,568,000 | -12,853,000 |
| Depreciation & Amortization | 7,000 | 11,000 |
| Stock Based Compensation | 730,000 | 913,000 |
| Change in Working Capital | 342,000 | -1,280,000 |
| Operating Cash Flow | -14,904,000 | -12,333,000 |
| Investing Activities | ||
| Capital Expenditure | 0 | -22,000 |
| Investments | 0 | -22,000 |
| Investing Cash Flow | 0 | 104,000 |
| Financing Activities | ||
| Debt Repayment | 0 | 0 |
| Common Stock Issued/Repurchased | 14,999,000 | 7,338,000 |
| Dividends Paid | 0 | 0 |
| Financing Cash Flow | 14,032,000 | 7,359,000 |
| Summary | ||
| Free Cash Flow | -14,904,000 | -12,355,000 |
| Net Change in Cash | -872,000 | -4,870,000 |